Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE AND PRILOCAINE versus ROMVIMZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE AND PRILOCAINE versus ROMVIMZA.
LIDOCAINE AND PRILOCAINE vs ROMVIMZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and prilocaine are amide-type local anesthetics that stabilize neuronal membranes by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
ROMVIMZA (romipegsim) is a recombinant fusion protein that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates the GLP-1 receptor, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying, leading to improved glycemic control.
Apply 2.5 g cream (lidocaine 25 mg/prilocaine 25 mg) to intact skin under occlusive dressing; maximum single application area 400 cm², maximum application time 4 hours. For genital mucous membranes: apply 5-10 g for 5-10 minutes without occlusion. Not recommended for dental use.
Intravenous administration of 3 mg/kg once every 3 weeks.
None Documented
None Documented
Lidocaine: 1.5-2 hours; prilocaine: 1.5-2 hours. In hepatic impairment, half-life may be prolonged up to 2-3 times.
Terminal elimination half-life is 14-18 hours in healthy adults, providing once-daily dosing suitability.
Renal excretion of metabolites (lidocaine: 70-80% as 4-hydroxy-2,6-xylidine and conjugates; prilocaine: 85-95% as o-toluidine metabolites and conjugates). Less than 10% of parent drugs excreted unchanged.
Primarily renal (75-80% as unchanged drug) with 20-25% fecal elimination via biliary secretion.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic